| Ivan Lorenzo Viera- San Martin, MSN | |
|
78 Plaza Fabiola, Estancias De Cerro Gordo, Vega Alta, PR 00692-9125 | |
| (787) 717-2568 | |
| Not Available |
| Full Name | Ivan Lorenzo Viera- San Martin |
|---|---|
| Gender | Male |
| Speciality | Clinical Nurse Specialist - Gerontology |
| Location | 78 Plaza Fabiola, Vega Alta, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144787458 | NPI | - | NPPES |
| 1187382 | Other | PR | DRIVER LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SG0600X | Clinical Nurse Specialist - Gerontology | E1779 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ivan Lorenzo Viera- San Martin, MSN 78 Plaza Fabiola, Estancias De Cerro Gordo, Vega Alta, PR 00692-9125 Ph: (787) 717-2568 | Ivan Lorenzo Viera- San Martin, MSN 78 Plaza Fabiola, Estancias De Cerro Gordo, Vega Alta, PR 00692-9125 Ph: (787) 717-2568 |
News Archive
Arrowhead Research Corporation, a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate.
Award-winning Lutherville agency, Barb Clapp Advertising & Marketing (BCAM), is pleased to announce the addition of a new client for the growing firm. BCAM will provide the LifeSpan Network, based in Columbia, MD, with public relations services.
More than a quarter of cancer survivors who still smoke have not been advised to quit smoking by their health care providers in the last year, according to a study published by researchers at Fox Chase Cancer Center in the current issue of the Journal of General Internal Medicine.
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Women may have a slightly higher risk of death than men in the 30 days following an acute coronary syndrome (ACS; such as heart attack or unstable angina), but this difference appears attributable to factors such as severity and type of ACS, clinical differences and angiographic severity according to a study in the August 26 issue of JAMA.
› Verified 1 days ago